CKD Screening in Developing Countries. The case of Jalisco, Mexico.
|
|
- Ezra Pearson
- 5 years ago
- Views:
Transcription
1 CKD Screening in Developing Countries. The case of Jalisco, Mexico. Hospital Civil de Guadalajara. Hospitales Civiles de Guadalajara Foundation University of Alberta, Edmonton, CA
2 Jalisco, Mexico.
3 Jalisco in numbers GDP (million) $ US 68,373 Annual Income per capita $ US 14,651 Population (m) 7.35 Life expectancy at birth (y) 75.6 HDI 0.82 Fertility rate 2.37 Population with medical insurance (m) 4.7 Illiteracy (%) 4.4
4 CKD is frequent: ESRD Incidence & Prevalence in Jalisco is rising. per mliion population Incidence Prevalence year USRDS, 2013
5 Percent distribution of dialysis patients, by modality & year. % HD PD year USRDS, 2013
6 Etiology of ESRD. Incident Patients Unknown 31% Diabetes 58% Other 3% Hypertension 4% Chronic GN 6% REDTJAL, 2005
7 CKD is harmful: ESRD is among the 10 leading causes of death. Cardiovascular Diabetes Malignacies Accidental Liver Cirrhosis CVA COPD Pneumonia ESRD Rate per 100,000 population
8 DM Prevalence in Mexico. % Rull JA. Arch Med Res 2005; 36: , NSCD 1993, NHS 2000.
9 Hypertension Prevalence in Mexico % Rodriguez J. Arch Cardiol Mex 1998;68:
10 Obesity Prevalence in Mexico. % NHS 1993, 2000, 2006, 2012
11 CKD is Harmful: Survival on PD in Jalisco. Mortality rate: 19.2 in Jalisco vs 5.9 per 100 patients-years in the US Garcia GG, et al. JASN 18: , 2007
12 Survival on Dialysis Garcia GG, et al. JASN 18: , 2007
13 CKD is Expensive: 1 billion dollars spent on 65,000 dialysis patients Patients (n) Annual cost per patient (USD) Estmated annual cost USD (millions) Hemodialysis 19,097 13, CAPD 37,423 14,947.00* APD 8,215 16,874.00* Sub-Total 64, Cervantes M et al; Estudio de Insuficiencia Renal Crónica y Tratamiento Mediante Terapia de Substitución. Secretaria de Salud. México * Sanabria L, et al: unpublished data.
14 Mexican Health System 2000 Frenk J; Lancet 2003; 362:
15 Health Care in Mexico Distribution by Health Care System UNINSURED 34.9 IMSS 31.4 PRIVATE INSURANCE OTHER ISSSTE 5.5 SEGURO POPULAR
16 Limited Access to RRT: Acceptance rates are lower among the uninsured 500 Acceptance rates PMP Garcia G et al; Semin Nephrol 2010;30:3-7 Garcia G et al; Kidney Int 2005;Suppl 97: 58-61
17 Unequal Access to RRT: ESRD prevalence is lower among the uninsured Prevalence rate 1211 PMP Garcia G et al; Semin Nephrol 2010;30:3-7 Garcia G et al; Kidney Int 2005;Suppl 97: 58-61
18 Unequal access to Renal Transplantation: Transplant rates are lower among uninsured ESRD paients Transplant Rate 122 PMP Garcia G et al; Semin Nephrol 2010;30:3-7 Garcia G et al; Kidney Int 2005;Suppl 97: 58-61
19 CKD FREQUENT + HARMFUL + EXPENSIVE + UNEQUAL ACCESS TO RRT = PREVENTION
20 CKD Screening and Prevention Initiatives in Jalisco.! Population-based screening Targeted Screening -CKD screening program using mobile clinics Oportunistic Screening - CKD Screening on WKD! MDC Prevention Clinic!!!!
21 ! In operation since 1999 Diabetes Hypertension CA of Cervix HIV-AIDS Cataracts Mobile Clinics Screening Programs
22 Mobile Clinics CKD Screening Program begins September, 2006! Mexico s Secretary of Health, Dr. Jose Cordova Villalobos, launches the CKD Screening Program. March, 2007
23 Equipment and Staff! 4 mobile units 4 Physicians 4 Nurses 4 Lab Technicians Undergraduate students from the University of Guadalajara Schools of Medicine, Nursing, and Nutrition
24 Clinical and Lab exams! CBC Blood Glucose, Creatinine, Urea Pap smear Eye examination Serum Lipids Urianalysis Estimated GFR (MDRD) BMI Blood Pressure
25 How does it work? Community leaders organize the screening program at their communities. - location of the van - estimated population - number of days of screening. Advertising campaign to alert for risk factors for kidney and CV disease and the benefits of early detection (flyers, radio and pulpit announcements during Sunday mass, mobile loudspeakers in public places, or door-to-door visits by local volunteers)
26 Follow-up of Findings During Screening Individuals found to have hypertension, proteinuria, diabetes or reduced egfr are informed of the findings. They are advised for: A) follow up with their own physician B) Those without phisicians are referred to our subsidized, protocol-driven, multidisciplinary prevention clinic.
27 Published Results Am J Kidney Dis 2010; 55:
28 Location of the Mobile Clinics Am J Kidney Dis 2010; 55:
29 Population-based Screening Am J Kidney Dis 2010; 55:
30 CKD Screening Initiatives.!! TARGETED SCREENING! -KEEP Mexico. Pilot Study.!
31 KEEP Jalisco Kidney International (2010) 77 (Suppl 116), S2 S8
32 KEEP Jalisco Participant Characteristics N= % 74% 60% 53 ± 13 56% 40% 20% 10% 0% Mean Age Women > High School Medical Insurance
33 Risk Factors 50% 44% 49% Participants (%) 38% 25% 13% 17% 23% 0% DM HTN DM + HTN Family Hx DM/HTN/CKD
34 Prevalence of Dipstick Proteinuria and egfr <60 KEEP Jalisco 40% 30% 31% 20% 10% 10% 0% PROTEINURIA egfr < 60 ml/min
35 Overall CKD Prevalence 40% 33% CKD Prevalence (%) 30% 20% 10% 7% 16% 10% 0% Overall Stage 1 Stage 2 Stage 3 Stages 4-5 1%
36 CKD Prevalence KEEP Jalisco versus KEEP US KEEP Jalisco KEEP US 40% CKD Prevalence (%) 30% 20% 10% 0% 33% 26% 16% 17% 10% 7% 5% 3% 1% 1% Overall Stage 1 Stage 2 Stage 3 Stages 4-5 * *
37 CKD Awareness 100% 91% 75% 50% 25% 0% 0% Aware of CKD Visited a MD in the previous year
38 CKD Screening Initiatives.!! TARGETED SCREENING! -Homeless Individuals!
39 CKD in Homeless Individuals Kidney International Supplements (2013) 3,
40 CKD in Homeless Homeless n= 269 NHS* n= 45,300 Age (y) ± ± Male (%) Known or New Diabetic (%) Known or new Hypertensive (%) egfr < 60 ml/ min/1.73 m p *NHS: National Health Survey 2000 Kidney International Supplements (2013) 3,
41 CKD in Homeless Persons Percentage Homeless Population-Based Stage 3 Stage 4Kidney International Stage 5 Supplements (2013) 3,
42 Addictions prevalence: Homeless vs General Population Kidney International Supplements (2013) 3,
43 HIV, Hepatitis B and C Prevalence: Homeless vs General Population ENSA 2000 = National Health Survey 2000 Kidney International Supplements (2013) 3,
44 CKD Screening Initiatives.!! TARGETED SCREENING! -High Risk Populations!
45 Targeting High-Risk Populations Archives of Medical Research 44 (2013)
46 Targeting High Risk Populations High Risk n= 9,619 NHS 2006* n= 33,366 Age (y) 55.5 ± ± Self-reported diabetes (%) 4,027 (41.9) 2,449 (7.34) Diabetes (%) 5,340 (56.1) 4,812 (14.42) Self-reported hypertension (%) SBP 140 or DBP 90 mmhg 4,956 (51.6) 5,505 (16.5) ,035 (52.5) 4,414 (43.2) BMI 30 kg/m 4,028 (42.8) 9,776 (29.3) p * NHS= National Health Survey 2006 Archives of Medical Research 44 (2013)
47 Targeting High Risk Populations 40 Percentage High Risk KEEP USA CKD Stage 1 Archives of Medical Research 44 (2013) Stage 2 Stage 3 Stage 4-5
48 CKD Screening Initiatives.!! OPORTUNISTIC SCREENING! -CKD screening on World Kidney Day!
49 CKD screening in WKD
50 Results egfr < 60 ml/min/1.73 m2 prevalence ranges between 1.7% in children and 6.4% in adults.
51 Conclusions Impaired kidney function is frequently detected when mobile units are used to perform screening in Jalisco, Mexico. Our data indicate that oportunistic screening on World Kidney Day may be useful for identifying individuals with CKD " KEEP is an effective CKD screening program for high-risk individuals, an CKD is severely under diagnosed and under recognized.
52 Conclusions CKD and its risk factors are highly prevalent among homeless persons in Jalisco, Mexico. Lack of awareness of having CKD, diabetes, and hypertension is highly common. Impaired kidney function, proteinuria, and cardiovascular risk factors are frequently detected when targeting a high-risk population. This suggests that trials of case-finding and intervention are feasible and warranted in Mexico and other low income settings.
53 THANKS!
CKD Prevention Program Protocol
CKD Prevention Program Protocol Taiwan Pathway as an example I. Understanding problems and situations of ESRD/CKD in Taiwan 1. Understanding the ESRD/CKD Burden 1) National Dialysis Registry since 1987
More informationEarly Detection of Chronic Kidney Disease (CKD)
Early Detection of Chronic Kidney Disease (CKD) Gregorio T. Obrador, MD, MPH Dean, Faculty of Health Sciences & School of Medicine Universidad Panamericana, Mexico City Adjunct Assistant Professor of Medicine,
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationDifference in practical dialysis therapy between East Asia and US/EU
Difference in practical dialysis therapy between East Asia and US/EU Jer-Ming Chang. M.D., Ph.D. 1 Professor, Attending physician, Kaohsiung Medical University Hospital; 2 Secretary General, Taiwan Society
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationUnited States Renal Data System (USRDS) International Data Collection Form
United States Renal Data System (USRDS) International Data Collection Form This form is designed to solicit information on the population of End-Stage Renal Disease (ESRD) patients in your country who
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationDialysis Initiation and Optimal Vascular Access: Outcomes and Mortality
Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationUpdates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG
Updates in Chronic Kidney Disease Management Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG No disclosures Research Funding: NIH, Blue Shield of California Foundation Objectives
More informationClinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria
Clinical Approach to the Patient At-Risk for Kidney Disease: Rationale for Testing for Serum Creatinine and Albuminuria Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationmorbidity & mortality
morbidity & mortality esrd introduction of ESRD treatment. We examine these concerns throughout the ADR, particularly in Chapter One. This year we focus on infectious complications, especially those related
More informationCOST MANAGEMENT: HOW CONVENIENT IS HOME HEMODIALYSIS?
Unione Europea Bando "Aiuti a Sostegno dei Cluster Tecnologici Regionali " COST MANAGEMENT: HOW CONVENIENT IS HOME HEMODIALYSIS? Maria Pia dell Oglio, Clinical Pathologist, Ph.D BACKGROUND Renal replacement
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationChronic kidney disease-what can you do and when to refer?
Chronic kidney disease-what can you do and when to refer? Dr Goh Heong Keong www.passpaces.com/kidney.htm Outline of Lecture Introduction Epidemiology of CKD in Malaysia/ World Complications of CKD What
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationSupplementary Online Content
Supplementary Online Content Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based
More informationCHAPTER 2. Prevalence of Renal Replacement Therapy for End Stage Kidney Disease
CHAPTER 2 Prevalence of Renal Replacement Therapy for End Stage Kidney Disease Summarising the number of prevalent renal replacement therapy patients in Australia and New Zealand, the prevalence rate per
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationAJNT. Special Article. Renal Replacement Therapy in Sudan, Sarra Elamin 1*, Wafaa Obeid 2, Hasan Abu-Aisha 1. Abstract
. 2010 May;3(2):31-6 Special Article AJNT Renal Replacement Therapy in Sudan, 2009 Sarra Elamin 1*, Wafaa Obeid 2, Hasan Abu-Aisha 1 1. Sudan Peritoneal Dialysis program, Sudan 2. National center for kidney
More informationSection Questions Answers
Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension
More informationManagement of End Stage Renal Disease-Bangladesh Perspective
Send Orders for Reprints to reprints@benthamscience.net 108 The Open Urology & Nephrology Journal, 2014, 7, 108-112 Management of End Stage Renal Disease-Bangladesh Perspective Harun Ur Rashid * Open Access
More informationSTATEMENT OF THE NATIONAL KIDNEY FOUNDATION SUBMITTED TO THE HOUSE COMMITTEE ON APPROPRIATIONS;
STATEMENT OF THE NATIONAL KIDNEY FOUNDATION 30 EAST 33 RD STREET NEW YORK, NY 10016 SUBMITTED TO THE HOUSE COMMITTEE ON APPROPRIATIONS; SUBCOMMITTEE ON LABOR, HHS, EDUCATION, AND RELATED AGENCIES March
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationCARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017
CARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017 RENEGOTIATING LIFE WITH CHRONIC KIDNEY DISEASE CONSTANTINI
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationImproving global access to integrated ESKD care. David Harris 01/10/17
University of Sydney Westmead Hospital Improving global access to integrated ESKD care David Harris 01/10/17 the problem resources numbers GLOBAL 125/202 countries 6.73/7.24b (93%) ASIA 25/42 countries
More informationEPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas
EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas Disclosure of Interests AstraZeneca (scientific advisory board) Bayer
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationCardiovascular disease profile
Cardiovascular disease profile Kidney disease Background This chapter of the Cardiovascular disease profiles focuses on kidney disease and is produced by the National Cardiovascular Intelligence Network
More informationDisclosures. CKD/ESRD care among vulnerable populations. Objectives. Case: Ms. S 3/12/2016. Delphine Tuot, MDCM, MAS Assistant Professor of Medicine
Disclosures CKD/ESRD care among vulnerable populations I have nothing to disclose Delphine Tuot, MDCM, MAS Assistant Professor of Medicine Objectives Recognize disparities related to kidney health Learn
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationHypertension and Chronic Kidney Disease
Hypertension and Chronic Kidney Disease George Bakris, MD, F.A.S.N. Professor of Medicine Director, Hypertensive Diseases Unit University of Chicago School of Medicine Projected growth of the incident
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationLas dos caras de la cretinina sérica The two sides of serum creatinine
Las dos caras de la cretinina sérica The two sides of serum creatinine ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1
More informationThe National Quality Standards for Chronic Kidney Disease
The National Quality Standards for Chronic Kidney Disease Dr Robert Lewis Chief of Service, Wessex Kidney Centre, Portsmouth Specialist Committee Member Quality Standard for Chronic Kidney Disease, NICE
More informationJai R adhakrishnan, Radhakrishnan, MD Columbia University
Jai Radhakrishnan, MD Jai Radhakrishnan, MD Columbia University 1. The Patient-Centered Medical Home 2. CKD Clinic as the paradigm for PCMH? 3. Outcome data 4. The Columbia model 5. Limitations 6. Financial
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationGeriatric Nephrology. Murtener Tage
Geriatric Nephrology Murtener Tage 2014 Isabelle.Binet@kssg.ch www.nierenstiftung.ch Plan Geriatric nephrology The elderly with CKD The elderly on dialysis The elderly in transplantation Plan Geriatric
More informationManaging Progressive Kidney Disease Andrew S. Narva, MD
Managing Progressive Kidney Disease Andrew S. Narva, MD U.S. Department of Health and Human Services National Institute of Health Managing Progressive Kidney Disease Standards of care for patients with
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationCase 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
More informationLong-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota
Long-term Non-ESRD Kidney Donor Risks Arthur Matas Dept Surgery University of Minnesota Conflict of Interest Disclosure I have no relevant financial relationships to disclose No off label use will be discussed
More informationMichigan s Diabetes Prevention and Control Program & National Kidney Foundation Michigan: A Successful Partnership
Michigan s Diabetes Prevention and Control Program & National Kidney Foundation Michigan: A Successful Partnership Dan Diepenhorst, MI DPCP diepenhorstd@michigan.gov Linda Smith-Wheelock, NKFM lsmith-wheelock@mkfm.org
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities
Chapter 1: Incidence, Prevalence, Patient Characteristics, and Treatment Modalities INCIDENCE In 2015, there were 124,114 newly reported cases of ESRD; the unadjusted (crude) incidence rate was 378 per
More information2008 Dialysis Facility Report
iii Purpose of the Report Enclosed is the (DFR) for this facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR includes data specific to provider number(s): 102844 These
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationHo Jun Chin 1,2,3, Jeong Myeong Ahn 2, Ki Young Na 1,2, Dong-wan Chae 1,2,3, Tae Woo Lee 1,3, Nam Joo Heo 4 and Suhnggwon Kim 1,3.
Nephrol Dial Transplant (2010) 25: 413 419 doi: 10.1093/ndt/gfp512 Advance Access publication 25 September 2009 The effect of the World Kidney Day campaign on the awareness of chronic kidney disease and
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationThe National Kidney Foundation (NKF) is pleased to submit testimony regarding the impact of
STATEMENT OF THE NATIONAL KIDNEY FOUNDATION 30 EAST 33 RD STREET NEW YORK, NY 10016 SUBMITTED TO THE HOUSE COMMITTEE ON APPROPRIATIONS; SUBCOMMITTEE ON LABOR, HHS, EDUCATION, AND RELATED AGENCIES IN SUPPORT
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationAn update on the obesity epidemics in CKD and in ESRD. Does it really matter?
EURECA-m 2011 An update on cutting-edge Cardiovascular and Renal Medicine themes. An update on the obesity epidemics in CKD and in ESRD. Does it really matter? Francesca Mallamaci BMI>30 25 Ireland 20
More informationEstimated expenditure for the treatment of diabetes mellitus in Mexico Aremis Villalobos a and Leticia Ávila b
Estimated expenditure for the treatment of diabetes mellitus in Mexico Aremis Villalobos a and Leticia Ávila b a. El Colegio de México; avillalobos@colmex.mx b. Instituto Nacional de Salud Pública; leticia.avila@insp.mx
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationChapter 2. Prevalence of End Stage Kidney Disease. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015
Chapter 2 Prevalence of End Stage Kidney Disease 2016 ANZDATA Registry 39th Annual Report Data to 31-Dec-2015 Renal Replacement Therapy Table 2.1 shows the prevalence (pmp) of renal replacement therapy
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationTransplant Options for Patients: Choices and Consequences. Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital
Transplant Options for Patients: Choices and Consequences Olwyn Johnston Medical Director Kidney Transplantation Vancouver General Hospital BC Kidney Days October 6 th 2017 Non contributory Conflict of
More informationImpact of APD on Sleep
Impact of APD on Sleep Sydney C.W. Tang The University of Hong Kong, Queen Mary Hospital, Hong Kong, China APD Symposium: Peritoneal Dialysis Update 26 Mar 2017, Hong Kong Sleep apnea in ESRD General population:
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationCHAPTER 2. Prevalence of Renal Replacement Therapy for End Stage Kidney Disease
CHAPTER 2 Prevalence of Renal Replacement Therapy for End Stage Kidney Disease Summarising the number of prevalent renal replacement therapy patients in and, the prevalence rate per million population
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationOptions in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology
Options in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology CKD Classification Stage Description GFR (ml/min/1.73.m2) 1 Kidney
More informationKEEP 2.0 Annual Data Report Chapter Five
KEEP 2. Annual Data Report Chapter Five Figure 5.1 percent distribution of KEEP participants with elevated serum creatinine levels, overall & by age 16 Percent of participants 12 8 4 All
More informationKaty Trinkley PharmD, BCACP Tiffany Goldberg Pharm D Candidate Katie Heist MD
Katy Trinkley PharmD, BCACP Tiffany Goldberg Pharm D Candidate Katie Heist MD Metformin: Only oral diabetes medication with proven benefits on cardiovascular morbidity and mortality Inexpensive medication
More informationPrimary Care Physicians and Clinicians. XXX on behalf of the Upper Midwest Fistula First Coalition. Chronic Kidney Disease (CKD) Resources
August 10, 2007 To: From: RE: Primary Care Physicians and Clinicians XXX on behalf of the Upper Midwest Fistula First Coalition Chronic Kidney Disease (CKD) Resources Caring for patients with chronic kidney
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationOnline clinical pathway for chronic kidney disease (CKD) in primary care. February 27, 2015 Dr. Kerry McBrien University of Calgary
Online clinical pathway for chronic kidney disease (CKD) in primary care February 27, 2015 Dr. Kerry McBrien University of Calgary FACULTY/PRESENTER DISCLOSURE Faculty: Kerry McBrien Relationships with
More information